How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

63,564 results for

Type 1 Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Diabetes - type 1: Scenario: Management of children and young people with type 1 diabetes

based the recommendations on alcohol on advice in the I SPAD consensus guidelines for the management of type 1 diabetes mellitus in children and adolescents published by the International Society for Pediatric and Adolescent Diabetes (ISPAD) [ ], which has been updated [ ], and on information on the Diabetes UK website ( ). Advice on exercise NICE found limited evidence on the effects of exercise in children and young people with type 1 diabetes. However, the GDG noted that, in general (...) [ ], the Association of Children's Diabetes Clinicians and British Society for Paediatric Endocrinology and Diabetes (BSPED) Clinical guideline. Management of type 1 diabetes mellitus during illness in children and young people under 18 years (sick day rules) [ ], the ISPAD Clinical Practice Consensus Guidelines 2018: sick day management in children and adolescents with diabetes published by the International Society for Pediatric and Adolescent Diabetes (ISPAD) [ ], and the National Service Framework for Children

2019 NICE Clinical Knowledge Summaries

122. Diabetes - type 1: Scenario: Management of adults with type 1 diabetes

information on managing diabetes during a period of illness is available on the Diabetes UK website ( ). Basis for recommendation Managing a period of illness These recommendations are extrapolated from the Association of Children's Diabetes Clinicians and British Society for Paediatric Endocrinology and Diabetes (BSPED) Clinical guideline. Management of type 1 diabetes mellitus during illness in children and young people under 18 years (sick day rules) [ ], the ISPAD Clinical Practice Consensus (...) Diabetes - type 1: Scenario: Management of adults with type 1 diabetes Scenario: Management - adults | Management | Diabetes - type 1 | CKS | NICE Search CKS… Menu Scenario: Management - adults Diabetes - type 1: Scenario: Management of adults with type 1 diabetes Last revised in July 2020 Scenario: Management of adults with type 1 diabetes From age 18 years onwards. What initial care and support should I offer an adult with type 1 diabetes? Ensure that an is set up for the person

2019 NICE Clinical Knowledge Summaries

123. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo)

for once-daily use for the treatment of diabetes mellitus (type 1 and type 2) in adults. In people with type 2 diabetes, it can be given together with other anti-hyperglycaemic medicinal products. T oujeo is not bioequivalent to insulin glargine 100 units/ml (Lantus) and dose adjustment is needed when patients are switched from Lantus or other basal insulins to T oujeo or vice versa (MHRA Drug Safety Update April 2015). T oujeo has a flatter and more prolonged (up to 36 hours) profile of insulin (...) on its pharmacodynamic and pharmacokinetic profiles, is associated with a lower risk of hypoglycaemia. The main phase 3 study of T oujeo in adults with type 1 diabetes (EDITION 4) is reviewed in the evidence summary on type 1 diabetes. In EDITION 1 (n=807), EDITION 2 (n=811) and EDITION 3 (n=878), once-daily insulin glargine 300 units/ml (T oujeo) was non-inferior to once-daily insulin glargine 100 units/ml (Lantus) in Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml

2015 National Institute for Health and Clinical Excellence - Advice

124. Type 2 diabetes mellitus

cardiovascular disease risk in people with a higher BMI. The committee noted Type 2 diabetes mellitus: medicines optimisation priorities (KTT12) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 6 of 10that previous NICE recommendations based on GLP-1 mimetics considered liraglutide at a dose of 1.2 mg and that the LEADER trial is not sufficient evidence by itself to recommend a dosage of 1.8 mg. Additionally, it was noted (...) marketing authorisation that allows the use of the biosimilar(s) in the same indication. For more information on the insulin glargine biosimilar, Abasaglar, see NICE's evidence summary on diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar). Practice examples and shared learning There are NICE shared learning case studies relating to type 2 diabetes, showing how NICE guidance and standards have been put into practice by some NHS organisations. These include: Supporting

2015 National Institute for Health and Clinical Excellence - Advice

125. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan (Abstract)

(nonexposure group), aged 20-79 years, were included between 1 April 2006 and 31 May 2015. Patients with a history of diabetes mellitus or receipt of antidiabetes treatment were excluded. Covariates were adjusted by using propensity score matching; the associations were analyzed between risk of new-onset type 2 diabetes and the duration of antidepressant use/dose of antidepressant in the exposure and nonexposure groups by using Cox proportional hazards models. Changes in glycated hemoglobin (HbA1c) level (...) Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan This study aimed to reveal the associations between the risk of new-onset type 2 diabetes mellitus and the duration of antidepressant use and the antidepressant dose, and between antidepressant use after diabetes onset and clinical outcomes.In this large-scale retrospective cohort study in Japan, new users of antidepressants (exposure group) and nonusers

2020 EvidenceUpdates

126. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Ambarish Pandey et al. Circulation . 2020 . Show details Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Authors # , # , , , , , , , , , , Affiliations 1 Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (A.P., K.V.P., D.K.M., J.D.B.). 2 Department of Biostatistics and Data Science (J.L.B., S.A.G.), Wake Forest (...) Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage

2020 EvidenceUpdates

127. Pre-conception care for women with type 1 or type 2 diabetes: a mixed methods study exploring uptake of pre-conception care

for the delivery of PCC to women with pre-existing diabetes mellitus and to ensure that the correct expertise is available so that opportunities for advice giving are maximised. Relationships between women and health professionals should be based on a partnership approach that encourages mutual trust and respect, focusing on positive change rather than negative outcomes. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female (...) Pre-conception care for women with type 1 or type 2 diabetes: a mixed methods study exploring uptake of pre-conception care Pre-conception care for women with type 1 or type 2 diabetes: a mixed methods study exploring uptake of pre-conception care Pre-conception care for women with type 1 or type 2 diabetes: a mixed methods study exploring uptake of pre-conception care Earle S, Tariq A, Komaromy C, Lloyd CE, Karamat MA, Webb J & Gill PS Record Status This is a bibliographic record

2017 Health Technology Assessment (HTA) Database.

128. Metformin?s role in type 1 diabetes: the removal trial

Tanner, MD, associate editor, clinical correlations Image courtesy of Wikimedia Commons References Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet . 1998;352(9131):854-865. Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism . 2015;64(12):1629-1639. Libman IM, Pietropaolo M, Arslanian SA, Laporte RE, Becker DJ. Changing (...) J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. Anderson JJA, Couper JJ, Giles LC, et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. J Clin Endocrinol Metab . 2017;102(12):4448-4456. Ziaee A, Esmailzadehha N, Honardoost M. Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus. Pak J Med Sci

2019 Clinical Correlations

129. Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes

Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes ssociation of Children’s Diabetes Clinicians Clinicians Version 4, May 2018 Review 2021 Authors: SM Ng, E Williams, F Ackland, C Burren, J Edge, E Hind, A McAulay, Bill Lamb 1 SETTING Children and young people with diabetes mellitus PATIENTS Children and young people with diabetes mellitus Guidance • Definition of hypoglycaemia in children with diabetes is a blood glucose 4.0mmol/L, Retest 20-30 minutes later (...) and caregivers, especially when there is a high risk of severe hypoglycaemia. Education on administration of glucagon is essential Blood glucose monitoring should be performed prior to exercise, and extra carbohydrates should be consumed based on the blood glucose level and the expected intensity and duration of the exercise REFERENCE 1. NICE (2015) Diabetes (type 1 and type 2) in children and young people. NICE guideline NG18 www.nice.org.uk/guidance/ng18 2. ISPAD Clinical Practice Consensus Guidelines 2014

2020 British Society for Paediatric Endocrinology and Diabetes

130. Care of the Well Child-Newly Diagnosed with Type 1 Diabetes

Care of the Well Child-Newly Diagnosed with Type 1 Diabetes Version 4, Dec 2019 Review 2022 Authors: J Chizo Agwu, SM Ng, A Timmis, C Moudiotis, K. Matyka,, N.P.Wright, M. Kershaw S.Bahl, A. Alston . N Trevelyan Page of 7 1 ssociation of Children’s Diabetes Clinicians Clinical Guideline Care of the well child, newly diagnosed with Type 1 Diabetes Mellitus SETTING Insert hospital name FOR STAFF Medical and nursing staff PATIENTS Children with diabetes and their families (...) , Pescovitz OH, DiMeglio LA. Autoimmune thyroid dysfunction in children with type1 diabetes mellitus: screening guidelines based on a retrospective analysis. J.Pediatr.Endocrinol.Metab. 2003;16:1111-7. 9. Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch.Dis.Child. 2005;90:411-4. 10. Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW

2020 British Society for Paediatric Endocrinology and Diabetes

131. Diabetes Mellitus and Pregnancy Type 1 & 2

Diabetes Mellitus and Pregnancy Type 1 & 2 April 2014 Please be informed that the PSBC obstetric guideline you are looking for Diabetes Mellitus and Pregnancy Type 1 & 2 is under revision but still available by request. An updated clinical practice guideline is available through the: “Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada”. See Chapter 36 for Diabetes and Pregnancy. http://guidelines.diabetes.ca/Browse/Chapter36 (...) The PSBC guideline for Gestational Diabetes Mellitus Screening and Diagnosis is also being revised. West Tower, 350-555 West 12th Avenue Vancouver, BC V5Z 3X7 Main Line: 604.877.2121 Fax: 604.872.1987 www.perinatalservicesbc.ca

2014 British Columbia Perinatal Health Program

132. Hormone replacement therapy for women with type 1 diabetes mellitus. Full Text available with Trip Pro

Hormone replacement therapy for women with type 1 diabetes mellitus. There is conflicting information about the impact of the menopause on glycaemic control amongst women with type 1 diabetes. Some menopausal women with type 1 diabetes are treated with hormone replacement therapy (HRT) but the effects of this treatment have, to date, not been established.To assess the effects of HRT for women with type 1 diabetes mellitus.We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL and PsycINFO (...) from their inception to June 2012. The last search was run for all databases on 18 June 2012.We selected randomised controlled trials or controlled clinical trials that involved peri- or postmenopausal women with type 1 diabetes undergoing HRT as an intervention.Two researchers independently applied the inclusion criteria to the identified studies and assessed risk of bias. Disagreements were resolved by discussion or by intervention by a third party. Descriptive analysis was conducted

2013 Cochrane

133. Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis

Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

134. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care.

and Department of Defense (VA and DoD) healthcare delivery systems, which includes Veterans, deployed and non-deployed Active Duty Service Members, and their adult family Refer to the original guideline document for specific populations for key questions. Note : This clinical practice guideline (CPG) does not provide recommendations for the management of DM in children, adolescents, or pregnant/nursing women. General approach to type 2 diabetes mellitus care Shared decision-making Individualized diabetes (...) a diagnosis of type 2 diabetes mellitus (T2DM). If the percentage is less than 80%, then data must have been reported separately for this patient subgroup. Key Question Specific Criteria For KQ 1, acceptable study designs included SRs, randomized controlled trials (RCTs), including follow-up studies of RCTs, cohorts and pre-planned, prospective analyses of those studies. Retrospective analyses were not included. For KQs 2-4, 8, and 9, acceptable study designs included SRs of RCTs and/or individual RCTs

2017 National Guideline Clearinghouse (partial archive)

135. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Full Text available with Trip Pro

cotransporter-2. Appendix Table 1. Summary of Clinical Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 1. Summary of Clinical Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 2. Summary of Intermediate Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 2. Summary of Intermediate Outcomes for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 3. Summary of Harms for Oral (...) Pharmacologic Treatment of Type 2 Diabetes Mellitus Appendix Table 3. Summary of Harms for Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus Recommendations Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Metformin is effective in reducing glycemic levels, is associated with weight loss and fewer hypoglycemic episodes

2017 American College of Physicians

136. Oral glucose-lowering agents in type 2 diabetes mellitus — an update

Oral glucose-lowering agents in type 2 diabetes mellitus — an update '); } else { document.write(' '); } ACE | Oral glucose-lowering agents in type 2 diabetes mellitus — an update Search > > Oral glucose-lowering agents in type 2 diabetes mellitus — an update - Oral glucose-lowering agents in type 2 diabetes mellitus — an update Published on 3 July 2017 This Appropriate Care Guide (ACG) highlights the importance of selecting agents based on drug and patient profiles to individualise care (...) ; and incorporates latest updates on oral glucose-lowering agents such as SGLT-2 inhibitors and DPP-4 inhibitors, their clinical and cost-effectiveness, safety and appropriate use in patients. Download the PDF below to access the full ACG. Key Messages 1. Establish patient-centred glycaemic targets. 2. Individualise treatment plans based on drug and patient profiles. 3. Select metformin as the initial glucose-lowering agent as it has long-term efficacy and safety data. 4. Use second generation sulfonylureas when

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

137. Gliclazide for the treatment of type 2 diabetes mellitus

Gliclazide for the treatment of type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Gliclazide for the treatment of type 2 diabetes mellitus Search > > Gliclazide for the treatment of type 2 diabetes mellitus - Gliclazide for the treatment of type 2 diabetes mellitus Published on 3 May 2017 Guidance Recommendations Following an evaluation of gliclazide for the treatment of type 2 diabetes mellitus, gliclazide 80mg immediate release tablet is recommended for listing on the MOH (...) Standard Drug List 1 (SDL1) by the MOH Drug Advisory Committee in view of its better safety profile compared to other sulfonylureas and low annual cost of subsidy. This recommendation means that subsidies will apply to gliclazide 80mg immediate release tablet for the indications registered in Singapore: Non-insulin-dependent diabetes, in association with an adapted diet, in cases where dietary measures alone provide inadequate control of blood glucose levels. Gliclazide 60mg modified release tablet

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

138. Initiating basal insulin in type 2 diabetes mellitus

Initiating basal insulin in type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Initiating basal insulin in type 2 diabetes mellitus Search > > Initiating basal insulin in type 2 diabetes mellitus - Initiating basal insulin in type 2 diabetes mellitus Published on 20 November 2017 This Appropriate Care Guide (ACG) continues from the ACG on oral glucose-lowering agents in type 2 diabetes mellitus (T2DM) and highlights the importance of not delaying insulin therapy. It provides (...) clinicians with a practical guide on initiating basal insulin in T2DM and how to prevent and manage hypoglycaemia. Download the PDF below to access the full ACG. Key Messages 1. Start insulin therapy if glycaemic goals are not met on oral glucose-lowering agents alone. 2. Initiate with basal insulin, such as intermediate- or long-acting insulin. 3. When initiating insulin, review concomitant oral glucose-lowering agents. Continue metformin +/- SGLT-2 inhibitors where appropriate. 4. Educate patients

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

139. Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation

, despite optimized use of insulin therapy and conventional blood glucose monitoring • Inability to recognize, or communicate about, symptoms of hypoglycemia Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glucose; Humans Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address for correspondence Evidence (...) Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Continuous

2018 Health Technology Assessment (HTA) Database.

140. Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment

with continuous glucose monitoring. The high ongoing cost of continuous glucose monitoring devices was seen as the greatest barrier to their widespread use. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glucose; Humans; Technology Assessment, Biomedical Language Published English Country of organisation Canada Province or state Ontario English summary An English language summary is available. Address (...) Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality

2018 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>